Journals / Medicine Science / 2018 / Cilt: 7 - Sayı: 3

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients

Pages
600–603
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Larger-scale and longtime studies are required for a better understanding of the genotoxicity of TDF.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tenofovir disoproxil fumarate (TDF) is an acyclic nucleotide reverse transcriptase inhibitor used as antiviral therapeutic drug in hepatitis B virus (HBV) infection treatment.
📊
Key Findings & Data:A total of 30 HBV-infected patients were included in this study: 10 were untreated, 10 took therapy for 6 months, 10 took therapy for 12 months and a further 15 were control group.
💡
Conclusion & Impact:Larger-scale and longtime studies are required for a better understanding of the genotoxicity of TDF.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Tenofovir disoproxil fumarate (TDF) is an acyclic nucleotide reverse transcriptase inhibitor used as antiviral therapeutic drug in hepatitis B virus (HBV) infection treatment. We investigated whether HBV itself or TDF could enhance genotoxicity in HBV infected patients. A total of 30 HBV-infected patients were included in this study: 10 were untreated, 10 took therapy for 6 months, 10 took therapy for 12 months and a further 15 were control group. We used the micronucleus test (MN) and mitotic index (MI) to assess the genotoxic effects of TDF. MN and MI frequency were significantly increased in all the HBV-infected patient groups when compared to control. However, significant differences were not found between different time points within the therapy groups. The current data indicate that chronic HBV infection without treatment has an effect on MN and MI. TDF administration at therapeutic doses for 12 months also did not reduce the MI and MN, suggesting its protective action against HBV induced genotoxic damage. Larger-scale and longtime studies are required for a better understanding of the genotoxicity of TDF.

🔖

Cite This Article

KORKMAZ, S., YÜKSEL, Ş., ERSOY, Y. (2018). The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients. Medicine Science, Cilt: 7 - Sayı: 3, 600–603. https://ajindex.com/articles/277606

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Bayram S, Topaktas M. Confirmation of the chromosome damaging effects of lamivudine in In vitro human peripheral blood lymphocytes. Environmental Mol Mutagenesis. 2008;49:328-33. Blackadar CB. Hepatocellular carcinoma and other liver diseases among Greenlanders chronically infected with hepatitis B virus: a population-based study. J Natl Cancer Inst. 2012;104:1515–6.
  2. Brüning A, Burger P, Gingelmaier A, et al. The HIV reverse transcriptase inhibitor tenofovir induces cell cycle arrest in human cancer cells. Invest New Drugs. 2012;30:1389-95.
  3. Buti M, Homs M. Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol. 2012;6:413-21. de Almeida TM, Leitão RC, Andrade JD, et al. Detection of micronuclei formation and nuclear anomalies in regenerative nodules of human cirrhotic livers and relationship to hepatocellular carcinoma. Cancer Genet Cytogenet. 2004;150:16-21.
  4. Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013;58:505–13.
  5. Idilman R, Gunsar F, Koruk M, et al. Yurdaydin C. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. J Viral Hepat. 2015; 22:504-10.
  6. Kim HJ, Cho JY, KimYJ, et al. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean J Intern Med. 2015;30:32-41.
  7. Kurtoglu EL, Yuksel S. Genotoxic effects of Tacrolimus on Human Lymphocyte Cells, Russian J Genet. 2012;48:651-5.
  8. Leeansyah E, Cameron PU, Solomon A, Tet al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013;207:1157-65.
  9. Livezey KW, Negorev D, Simon D. Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat Research. 2002;505:63-74. Lourenço ED, do Amaral VS, Lehmann M, et al. Micronuclei induced by reverse transcriptase inhibitors in mononucleated and binucleated cells as assessed by the cytokinesis-block micronucleus assay. Genetics and Molecular Biology. 2010;33:756-60.
  10. Luzhna L, Kathiria P, Kovalchuk O. Micronuclei in genotoxicity assessment: from genetics to epigenetics and beyond. Front Genet. 2013; 4:13